Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by BVF Inc. IL

BVF Inc. IL reduced its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 37.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,715,893 shares of the company's stock after selling 3,420,000 shares during the period. Olema Pharmaceuticals makes up about 1.1% of BVF Inc. IL's holdings, making the stock its 22nd biggest holding. BVF Inc. IL owned approximately 9.98% of Olema Pharmaceuticals worth $33,324,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Barclays PLC grew its holdings in Olema Pharmaceuticals by 105.0% during the 3rd quarter. Barclays PLC now owns 94,915 shares of the company's stock worth $1,133,000 after acquiring an additional 48,614 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Olema Pharmaceuticals by 658.7% during the third quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company's stock worth $2,162,000 after purchasing an additional 157,171 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in Olema Pharmaceuticals by 80.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 212,246 shares of the company's stock worth $1,237,000 after purchasing an additional 94,651 shares in the last quarter. SG Americas Securities LLC increased its holdings in Olema Pharmaceuticals by 33.8% in the fourth quarter. SG Americas Securities LLC now owns 17,475 shares of the company's stock valued at $102,000 after buying an additional 4,419 shares during the last quarter. Finally, Vontobel Holding Ltd. acquired a new stake in Olema Pharmaceuticals during the fourth quarter valued at approximately $62,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Olema Pharmaceuticals Stock Performance

Shares of Olema Pharmaceuticals stock traded down $0.02 during trading on Friday, hitting $4.65. 301,984 shares of the stock were exchanged, compared to its average volume of 869,523. Olema Pharmaceuticals, Inc. has a 12 month low of $2.86 and a 12 month high of $16.62. The stock's fifty day moving average is $4.26 and its 200 day moving average is $6.42. The stock has a market cap of $317.88 million, a PE ratio of -2.12 and a beta of 2.03.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.12. Sell-side analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Analysts Set New Price Targets

OLMA has been the subject of a number of research analyst reports. Oppenheimer reiterated an "outperform" rating and issued a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th. JPMorgan Chase & Co. dropped their target price on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday, March 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a report on Monday, April 28th.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.